
What We’re Reading: Insurers Publicly Shamed; HHS Grants for COVID-19 Countermeasures; Medicare Obesity Drug Coverage
Patients and physicians are publicly shaming insurance companies on social media for the troublesome prior authorization process; HHS has awarded $1.4 billion in grants for the creation of new technologies and tools to prevent COVID-19 infection; Novo Nordisk has increased lobbying efforts to allow Medicare coverage of weight loss drugs.
Patients, Doctors Shame Insurers to Reverse Prior Authorization Denials
Patients and physicians have been publicly shaming insurance companies on social media to get drugs, tests, and treatments approved that were previously denied through the prior authorization process, according to
HHS Awards $1.4 Billion for COVID-19 Countermeasures
HHS has awarded $1.4 billion in grants through its Administration for Strategic Preparedness and Response (ASPR) to fund the development of tools and technologies to protect against COVID-19, according to
Novo Nordisk Boosts Lobbying for Obesity Drug Coverage
Novo Nordisk, creator of diabetes medication Ozempic and weight loss drug Wegovy, has increased its lobbying efforts in the past 6 months to push Congress to pass a bill that would lift Medicare restrictions against weight management treatment coverage, according to
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.